Article Details

BeiGene has terminated the clinical development program of the TIGIT antibody osperlimab ...

Retrieved on: 2025-04-04 13:50:45

Tags for this article:

Click the tags to see associated articles and topics

BeiGene has terminated the clinical development program of the TIGIT antibody osperlimab .... View article details on hiswai:

Excerpt

It was disclosed that osperlimab (BGB-A1217) is an investigational humanized IgG1 variant monoclonal antibody against TIGIT, after the company was ...

Article found on: www.yicaiglobal.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo